THE ARISING · Markets & Strategy
EU Medicines Committee Backs Baxdrostat for Hard-to-Control Blood Pressure
The European Commission still has to decide whether to authorize the medicine in the EU.
The European Medicines Agency’s human medicines committee recommended on November 12 that Baxfendy (baxdrostat) be authorized for adults whose blood pressure remains insufficiently controlled despite at least two antihypertensive medicines.
Baxdrostat suppresses production of aldosterone, a hormone that helps regulate salt and water balance. The committee cited randomized, placebo-controlled studies showing reductions in systolic and diastolic blood pressure. Those results describe blood pressure control, not proof that this medicine reduces strokes or heart attacks. The agency identified elevated potassium as its most common side effect.
The recommendation is not EU marketing authorization. The November meeting record lists the European Commission decision as pending, and EMA says the detailed European prescribing information will follow if authorization is granted.
The committee’s language also matters for who might be offered the medicine. Its recommendation is for adults whose pressure remains too high despite treatment, not for all adults with a new diagnosis. Because the trials measured blood pressure, the finding answers whether the drug can bring that number down in the studied setting. It does not settle how much benefit or harm patients might experience over longer follow-up, or how the treatment compares with every other option for hard-to-control hypertension. If the Commission authorizes it, clinicians will have the final prescribing information to consult, including how the drug should be used and what precautions apply.